The China Mail - Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

USD -
AED 3.672498
AFN 64.000326
ALL 82.68029
AMD 367.135014
ANG 1.790403
AOA 916.999809
ARS 1477.225982
AUD 1.448845
AWG 1.8
AZN 1.702453
BAM 1.715275
BBD 2.014515
BDT 123.02835
BGN 1.69088
BHD 0.377119
BIF 2970.641759
BMD 1
BND 1.294218
BOB 6.912067
BRL 5.176399
BSD 1.000241
BTN 93.880701
BWP 13.593527
BYN 2.900919
BYR 19600
BZD 2.011585
CAD 1.418275
CDF 2270.000387
CHF 0.808603
CLF 0.023386
CLP 920.39016
CNY 6.80385
CNH 6.80532
COP 3436.33
CRC 454.120897
CUC 1
CUP 26.5
CVE 96.704174
CZK 21.28265
DJF 178.120998
DKK 6.55597
DOP 58.769103
DZD 133.313032
EGP 49.508698
ERN 15
ETB 161.263403
EUR 0.877098
FJD 2.266103
FKP 0.756718
GBP 0.75655
GEL 2.645009
GGP 0.756718
GHS 11.278044
GIP 0.756718
GMD 73.000078
GNF 8764.059725
GTQ 7.63095
GYD 209.335368
HKD 7.84221
HNL 26.762262
HRK 6.609701
HTG 130.728584
HUF 310.600502
IDR 17859
ILS 2.997769
IMP 0.756718
INR 94.36415
IQD 1310.26771
IRR 1375050.000106
ISK 126.301278
JEP 0.756718
JMD 157.530312
JOD 0.708976
JPY 161.650502
KES 129.509862
KGS 87.449975
KHR 4014.99704
KMF 433.999764
KPW 900.00035
KRW 1536.095377
KWD 0.30962
KYD 0.833556
KZT 485.307724
LAK 21954.438817
LBP 89573.137575
LKR 336.229088
LRD 182.200101
LSL 16.441492
LTL 2.95274
LVL 0.60489
LYD 6.420634
MAD 9.379032
MDL 17.734997
MGA 4230.669724
MKD 54.081445
MMK 2099.450161
MNT 3580.242389
MOP 8.08004
MRU 39.918437
MUR 47.710173
MVR 15.450036
MWK 1734.46298
MXN 17.515645
MYR 4.089304
MZN 63.89854
NAD 16.441492
NGN 1378.749823
NIO 36.808525
NOK 9.913875
NPR 150.211581
NZD 1.770015
OMR 0.384494
PAB 1.000285
PEN 3.41073
PGK 4.389446
PHP 61.307995
PKR 278.373232
PLN 3.76004
PYG 6104.908659
QAR 3.645931
RON 4.597099
RSD 102.978994
RUB 77.741848
RWF 1464.86285
SAR 3.756188
SBD 8.051953
SCR 14.043416
SDG 600.000332
SEK 9.71586
SGD 1.29417
SHP 0.746601
SLE 24.795264
SLL 20969.503664
SOS 571.66663
SRD 37.319991
STD 20697.981008
STN 21.486987
SVC 8.751743
SYP 110.532098
SZL 16.431845
THB 33.380139
TJS 9.257398
TMT 3.5
TND 2.96472
TOP 2.40776
TRY 46.592504
TTD 6.797662
TWD 31.889202
TZS 2622.693046
UAH 44.895745
UGX 3671.108656
UYU 40.151731
UZS 12014.822286
VES 620.752985
VND 26300
VUV 119.950905
WST 2.785497
XAF 575.287334
XAG 0.017191
XAU 0.000247
XCD 2.70255
XCG 1.802627
XDR 0.716453
XOF 575.284811
XPF 104.593392
YER 238.625007
ZAR 16.461103
ZMK 9001.19602
ZMW 18.017813
ZWL 321.999592
  • RBGPF

    0.0000

    61.3

    0%

  • CMSC

    -0.0190

    22.046

    -0.09%

  • BCC

    2.1000

    79.76

    +2.63%

  • GSK

    0.8000

    51.89

    +1.54%

  • RIO

    1.0800

    95.11

    +1.14%

  • CMSD

    -0.0900

    21.93

    -0.41%

  • BTI

    1.0900

    62.48

    +1.74%

  • BP

    -0.1400

    37.72

    -0.37%

  • BCE

    0.0000

    23.2

    0%

  • NGG

    0.5900

    83.42

    +0.71%

  • JRI

    0.0100

    12.58

    +0.08%

  • RYCEF

    0.7000

    18.7

    +3.74%

  • AZN

    2.6600

    185.68

    +1.43%

  • RELX

    -0.2300

    30.92

    -0.74%

  • VOD

    0.0500

    13.86

    +0.36%

Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that, effective January 8, 2025, the Company granted 15,000 restricted stock units (RSUs) to New Employee 1, 15,000 RSUs to New Employee 2, and 45,000 RSUs to New Employee 3.

Text size:

The RSUs for New Employee 1 and New Employee 2 vest over one year starting from each employee's date of hire, and the RSUs for New Employee 3 vest equally over three years, with one-third of the shares vesting each year starting from New Employee 3's date of hire.

The RSUs for all three new employees were granted as an inducement material to each employee's acceptance of employment by the Company and were approved by the Compensation Committee of Jaguar's Board. Vesting of the RSUs is subject to each new employee's continued service with Jaguar through the applicable vesting dates.

About the Jaguar Health Family of Companies

Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Jaguar family company Napo Pharmaceuticals (Napo) focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states. Napo's crofelemer is FDA-approved under the brand name Mytesi® for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan and/or rare diseases. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar's Entheogen Therapeutics Initiative (ETI), is focused on developing novel prescription medicines derived from plants for mental health indications.

For more information about:

Jaguar Health, visit https://jaguar.health

Napo Pharmaceuticals, visit www.napopharma.com

Napo Therapeutics, visit napotherapeutics.com

Magdalena Biosciences, visit magdalenabiosciences.com

Visit the Make Cancer Less Shitty patient advocacy program on Bluesky, X, Facebook & Instagram

Forward-Looking Statements

Certain statements in this press release constitute "forward-looking statements." In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

Source: Jaguar Health, Inc.

Contact:

[email protected]

Jaguar-JAGX

SOURCE: Jaguar Health, Inc.

Z.Huang--ThChM